Literature DB >> 20809521

Islet-expressed TLR2 and TLR4 sense injury and mediate early graft failure after transplantation.

Bernd Krüger1, Na Yin, Nan Zhang, Anju Yadav, William Coward, Girdhari Lal, Weiping Zang, Peter S Heeger, Jonathan S Bromberg, Barbara Murphy, Bernd Schröppel.   

Abstract

Although islet transplantation is an effective treatment for Type 1 diabetes, primary engraftment failure contributes to suboptimal outcomes. We tested the hypothesis that islet isolation and transplantation activate innate immunity through TLR expressed on islets. Murine islets constitutively express TLR2 and TLR4, and TLR activation with peptidoglycan or LPS upregulates islet production of cytokines and chemokines. Following transplantation into streptozotocin-induced diabetic, syngeneic mice, islets exposed to LPS or peptidoglycan had primary graft failure with intra- and peri-islet mononuclear cell inflammation. The use of knockout mice showed that recipient CD8(+) T cells caused engraftment failure and did so in the absence of islet-derived DC. To mimic physiological islet injury, islets were transplanted with exocrine debris. Transplantation of TLR2/4(-/-) islets reduced proinflammatory cytokine production and improved islet survival. Stressed islets released the alarmin high-mobility group box protein 1 (HMGB1) and recombinant HMGB1 (rHMGB1) induced NFkB activation. NFkB activation was prevented in the absence of both TLR2 and TLR4. rHMGB1 pretreatment also prevented primary engraftment through a TLR2/4-dependent pathway. Our results show that islet graft failure can be initiated by TLR2 and TLR4 signaling and suggest that HMGB1 is one likely early mediator. Subsequent downstream signaling results in intra-islet inflammation followed by T-cell-mediated graft destruction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809521      PMCID: PMC3056019          DOI: 10.1002/eji.201040601

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  35 in total

1.  Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells.

Authors:  M Vives-Pi; N Somoza; J Fernández-Alvarez; F Vargas; P Caro; A Alba; R Gomis; M O Labeta; R Pujol-Borrell
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

2.  Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways.

Authors:  Bernd Schröppel; Nan Zhang; Peng Chen; Weiping Zang; Dongmei Chen; Kelly L Hudkins; William A Kuziel; Randall Sung; Jonathan S Bromberg; Barbara Murphy
Journal:  J Am Soc Nephrol       Date:  2004-07       Impact factor: 10.121

3.  The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets.

Authors:  Li Wen; Jian Peng; Zhenjun Li; F Susan Wong
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

4.  Destruction of islet isografts by severe nonspecific inflammation.

Authors:  M Nagata; Y Mullen; S Matsuo; M Herrera; M Clare-Salzler
Journal:  Transplant Proc       Date:  1990-04       Impact factor: 1.066

5.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.

Authors:  K Hoshino; O Takeuchi; T Kawai; H Sanjo; T Ogawa; Y Takeda; K Takeda; S Akira
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

6.  Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure.

Authors:  Saida Abdelli; Jeff Ansite; Raphael Roduit; Tiziana Borsello; Ippei Matsumoto; Toshiya Sawada; Nathalie Allaman-Pillet; Hugues Henry; Jacques S Beckmann; Bernhard J Hering; Christophe Bonny
Journal:  Diabetes       Date:  2004-11       Impact factor: 9.461

7.  Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation.

Authors:  R Bottino; L A Fernandez; C Ricordi; R Lehmann; M F Tsan; R Oliver; L Inverardi
Journal:  Diabetes       Date:  1998-03       Impact factor: 9.461

8.  Role of donor-derived monocyte chemoattractant protein-1 in murine islet transplantation.

Authors:  Bernd Schröppel; Nan Zhang; Peng Chen; Dongmei Chen; Jonathan S Bromberg; Barbara Murphy
Journal:  J Am Soc Nephrol       Date:  2004-12-15       Impact factor: 10.121

9.  Adenovirus transduction induces expression of multiple chemokines and chemokine receptors in murine beta cells and pancreatic islets.

Authors:  Nan Zhang; Bernd Schröppel; Dongmei Chen; Shuang Fu; Kelly L Hudkins; Haojiang Zhang; Barbara M Murphy; Randall S Sung; Jonathan S Bromberg
Journal:  Am J Transplant       Date:  2003-10       Impact factor: 8.086

10.  Elevated vascular endothelial growth factor production in islets improves islet graft vascularization.

Authors:  Nan Zhang; Anja Richter; Jenny Suriawinata; Sonal Harbaran; Jennifer Altomonte; Lin Cong; Haojiang Zhang; Keying Song; Marcia Meseck; Jonathan Bromberg; Hengjiang Dong
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

View more
  18 in total

1.  Physiologic Doses of Bilirubin Contribute to Tolerance of Islet Transplants by Suppressing the Innate Immune Response.

Authors:  Christopher A Adin; Zachary C VanGundy; Tracey L Papenfuss; Feng Xu; Mostafa Ghanem; Jonathan Lakey; Gregg A Hadley
Journal:  Cell Transplant       Date:  2016-07-07       Impact factor: 4.064

Review 2.  Islet inflammation in type 2 diabetes and physiology.

Authors:  Kosei Eguchi; Ryozo Nagai
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

3.  Extracellular factors and immunosuppressive drugs influencing insulin secretion of murine islets.

Authors:  V J Auer; E Janas; V Ninichuk; E Eppler; T S Weiss; S Kirchner; A M Otto; M J Stangl
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

4.  Proinflammatory Effects of Respiratory Syncytial Virus-Induced Epithelial HMGB1 on Human Innate Immune Cell Activation.

Authors:  Kempaiah Rayavara; Alexander Kurosky; Susan J Stafford; Nisha J Garg; Allan R Brasier; Roberto P Garofalo; Yashoda M Hosakote
Journal:  J Immunol       Date:  2018-10-01       Impact factor: 5.422

Review 5.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

6.  Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14.

Authors:  Sodam Kim; Sun Young Kim; John P Pribis; Michael Lotze; Kevin P Mollen; Richard Shapiro; Patricia Loughran; Melanie J Scott; Timothy R Billiar
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

Review 7.  Innate immunity in diabetes and diabetic nephropathy.

Authors:  Jun Wada; Hirofumi Makino
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

8.  The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88.

Authors:  John P Pribis; Yousef Al-Abed; Huan Yang; Domokos Gero; Hongbo Xu; Marcelo F Montenegro; Eileen M Bauer; Sodam Kim; Sangeeta S Chavan; Changchun Cai; Tunliang Li; Petra Szoleczky; Csaba Szabo; Kevin J Tracey; Timothy R Billiar
Journal:  Mol Med       Date:  2015-09-02       Impact factor: 6.354

9.  Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration.

Authors:  Wenji Piao; Yanbao Xiong; Lushen Li; Vikas Saxena; Kile D Smith; Keli L Hippen; Christina Paluskievicz; Marina Willsonshirkey; Bruce R Blazar; Reza Abdi; Jonathan S Bromberg
Journal:  Cell Rep       Date:  2020-01-28       Impact factor: 9.423

Review 10.  The innate immune system and transplantation.

Authors:  Conrad A Farrar; Jerzy W Kupiec-Weglinski; Steven H Sacks
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.